Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. Nektar Therapeutics, specializes in creating novel therapies aimed at selectively modulating pathways within the immune system that play critical roles in a wide range of serious diseases. Specifically in autoimmune disorders, Nektar's focus is on addressing imbalances in the immune system to restore the body’s self-tolerance mechanisms and achieve immune homeostasis. Nektar is headquartered in San Francisco, California, with additional manufacturing operations in Huntsville, Alabama.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.